Literature DB >> 28920557

Automated MicroSPECT/MicroCT Image Analysis of the Mouse Thyroid Gland.

Peng Cheng1, Brynn Hollingsworth2, Daniel Scarberry2, Daniel H Shen3, Kimerly Powell4, Sean C Smart5, John Beech5, Xiaochao Sheng1, Lawrence S Kirschner6, Chia-Hsiang Menq1, Sissy M Jhiang2.   

Abstract

BACKGROUND: The ability of thyroid follicular cells to take up iodine enables the use of radioactive iodine (RAI) for imaging and targeted killing of RAI-avid thyroid cancer following thyroidectomy. To facilitate identifying novel strategies to improve 131I therapeutic efficacy for patients with RAI refractory disease, it is desired to optimize image acquisition and analysis for preclinical mouse models of thyroid cancer.
METHODS: A customized mouse cradle was designed and used for microSPECT/CT image acquisition at 1 hour (t1) and 24 hours (t24) post injection of 123I, which mainly reflect RAI influx/efflux equilibrium and RAI retention in the thyroid, respectively. FVB/N mice with normal thyroid glands and TgBRAFV600E mice with thyroid tumors were imaged. In-house CTViewer software was developed to streamline image analysis with new capabilities, along with display of 3D voxel-based 123I gamma photon intensity in MATLAB.
RESULTS: The customized mouse cradle facilitates consistent tissue configuration among image acquisitions such that rigid body registration can be applied to align serial images of the same mouse via the in-house CTViewer software. CTViewer is designed specifically to streamline SPECT/CT image analysis with functions tailored to quantify thyroid radioiodine uptake. Automatic segmentation of thyroid volumes of interest (VOI) from adjacent salivary glands in t1 images is enabled by superimposing the thyroid VOI from the t24 image onto the corresponding aligned t1 image. The extent of heterogeneity in 123I accumulation within thyroid VOIs can be visualized by 3D display of voxel-based 123I gamma photon intensity.
CONCLUSIONS: MicroSPECT/CT image acquisition and analysis for thyroidal RAI uptake is greatly improved by the cradle and the CTViewer software, respectively. Furthermore, the approach of superimposing thyroid VOIs from t24 images to select thyroid VOIs on corresponding aligned t1 images can be applied to studies in which the target tissue has differential radiotracer retention from surrounding tissues.

Entities:  

Keywords:  CT; SPECT; cradle; mouse; radioiodine; thyroid

Mesh:

Substances:

Year:  2017        PMID: 28920557      PMCID: PMC5672640          DOI: 10.1089/thy.2017.0264

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  23 in total

1.  Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.

Authors:  Debyani Chakravarty; Elmer Santos; Mabel Ryder; Jeffrey A Knauf; Xiao-Hui Liao; Brian L West; Gideon Bollag; Richard Kolesnick; Tin Htwe Thin; Neal Rosen; Pat Zanzonico; Steven M Larson; Samuel Refetoff; Ronald Ghossein; James A Fagin
Journal:  J Clin Invest       Date:  2011-11-21       Impact factor: 14.808

Review 2.  Radioiodine for remnant ablation and therapy of metastatic disease.

Authors:  Christoph Reiners; Heribert Hänscheid; Markus Luster; Michael Lassmann; Frederik A Verburg
Journal:  Nat Rev Endocrinol       Date:  2011-08-09       Impact factor: 43.330

Review 3.  Targeted therapies for thyroid tumors.

Authors:  Steven I Sherman
Journal:  Mod Pathol       Date:  2011-04       Impact factor: 7.842

4.  Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

Authors:  Martin Schlumberger; Makoto Tahara; Lori J Wirth; Bruce Robinson; Marcia S Brose; Rossella Elisei; Mouhammed Amir Habra; Kate Newbold; Manisha H Shah; Ana O Hoff; Andrew G Gianoukakis; Naomi Kiyota; Matthew H Taylor; Sung-Bae Kim; Monika K Krzyzanowska; Corina E Dutcus; Begoña de las Heras; Junming Zhu; Steven I Sherman
Journal:  N Engl J Med       Date:  2015-02-12       Impact factor: 91.245

5.  Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine.

Authors:  James Nagarajah; Mina Le; Jeffrey A Knauf; Giuseppe Ferrandino; Cristina Montero-Conde; Nagavarakishore Pillarsetty; Alexander Bolaender; Christopher Irwin; Gnana Prakasam Krishnamoorthy; Mahesh Saqcena; Steven M Larson; Alan L Ho; Venkatraman Seshan; Nobuya Ishii; Nancy Carrasco; Neal Rosen; Wolfgang A Weber; James A Fagin
Journal:  J Clin Invest       Date:  2016-09-26       Impact factor: 14.808

6.  Multimodality rodent imaging chambers for use under barrier conditions with gas anesthesia.

Authors:  Chris Suckow; Claudia Kuntner; Patrick Chow; Robert Silverman; Arion Chatziioannou; David Stout
Journal:  Mol Imaging Biol       Date:  2008-08-05       Impact factor: 3.488

7.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; S M Jhiang
Journal:  Am J Med       Date:  1994-11       Impact factor: 4.965

8.  Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.

Authors:  Alan L Ho; Ravinder K Grewal; Rebecca Leboeuf; Eric J Sherman; David G Pfister; Desiree Deandreis; Keith S Pentlow; Pat B Zanzonico; Sofia Haque; Somali Gavane; Ronald A Ghossein; Julio C Ricarte-Filho; José M Domínguez; Ronglai Shen; R Michael Tuttle; Steve M Larson; James A Fagin
Journal:  N Engl J Med       Date:  2013-02-14       Impact factor: 91.245

9.  Segmentation and visual analysis of whole-body mouse skeleton microSPECT.

Authors:  Artem Khmelinskii; Harald C Groen; Martin Baiker; Marion de Jong; Boudewijn P F Lelieveldt
Journal:  PLoS One       Date:  2012-11-12       Impact factor: 3.240

10.  A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.

Authors:  Maria E Cabanillas; Martin Schlumberger; Barbara Jarzab; Renato G Martins; Furio Pacini; Bruce Robinson; Judith C McCaffrey; Manisha H Shah; Donald L Bodenner; Duncan Topliss; Corina Andresen; James P O'Brien; Min Ren; Yasuhiro Funahashi; Roger Allison; Rossella Elisei; Kate Newbold; Lisa F Licitra; Steven I Sherman; Douglas W Ball
Journal:  Cancer       Date:  2015-04-24       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.